|MDACC Study No:||2014-0152 (clinicaltrials.gov NCT No: NCT02071927)|
|Title:||A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a single agent and in Combination with Standard Therapy in Patients with Relapsed/ Refractory and/or newly diagnosed Leukemia and/or IDH-Mutated Myelodysplastic Syndrome|
|Principal Investigator:||Marina Konopleva|
|Treatment Agent:||Azacitidine; CB-839|
|Study Description:||The goal of Part I of this clinical research study is to find the highest |
tolerable dose of CB-839 either alone or in combination with azacitidine that
can be given to patients with newly diagnosed, relapsed, or refractory AML,
ALL, or MDS.
The goal of Part II of this study is to learn if the dose found in Part 1 of
the study can help to control the disease.
The safety of the study drug will be studied in both parts of this study.